Adults with hereditary angioedema (HAE) experience physical stress responses similar to those with other chronic conditions, such as the autoimmune condition immune thrombocytopenia (ITP), in which stress is usually not involved in disease flare-ups. A new study found that when faced with stressful tasks, HAE patients showed heart…
News
Biocryst Pharmaceuticals has acquired Astria Therapeutics, and with it navenibart, an investigational treatment to prevent swelling attacks in people with hereditary angioedema (HAE). Navenibart is being tested in the Phase 3 ALPHA-ORBIT trial (NCT06842823), which is recruiting patients, ages 12 and older with HAE type…
A 54-year-old man with sudden, unexplained abdominal pain was diagnosed with intestinal angioedema — marked by swelling of the gastrointestinal tract — linked to the use of the common blood pressure drug lisinopril, according to a case report. His symptoms resolved quickly after stopping treatment with the medication,…
The case of a new mother who developed severe acute allergic angioedema triggered by a common antibiotic was described by researchers in India in a new report, with the team seeking to stress the importance of early and “aggressive” treatment of reactions to even routinely used drugs. The woman,…
Dawnzera (donidalorsen), an injection therapy used to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), has been approved in the European Union as a preventive treatment for HAE patients 12 and older. That decision, by the European Commission, comes shortly after the therapy was…
People with hereditary angioedema (HAE) began experiencing symptom relief from swelling attacks of the larynx (voice box) or abdomen in less than two hours after taking oral Ekterly (sebetralstat). The finding comes from an interim analysis of data from the open-label extension (OLE) study,…
Kalvista Pharmaceuticals saw approximately $49 million in global revenue from Ekterly (sebetralstat) in the treatment’s initial six months on the market, according to a year-end update. Approved in mid-2025 as the first oral on-demand treatment for hereditary angioedema (HAE) in the U.S. and Europe, the therapy generated…
A rapid response to Ruconest (recombinant C1 esterase inhibitor) may support an otherwise difficult diagnosis of a rare form of hereditary angioedema (HAE) marked by normal levels of C1-inhibitor (C1-INH) protein, a study suggested. This form of the disease, HAE-nl-C1INH, is challenging to diagnose because there are…
Throughout 2025, the team at Angioedema News brought readers the latest updates on research, treatments, clinical trials, and real-world experiences related to angioedema. From progress in gene-editing approaches to insights into how patients manage swelling attacks, our goal has been to support people living with this rare condition…
Daily treatment with Orladeyo (berotralstat) oral granules led to early and sustained reductions in swelling attack rates in young children with hereditary angioedema (HAE), according to one-year interim data from an ongoing Phase 3 trial. The data, together with additional analyses on disease burden and patient experience, were presented…
Recent Posts
- Body stress signals in HAE match those of autoimmune disorder ITP
- Biocryst expands HAE treatment portfolio with Astria acquisition
- When executing a plan, each person must do the right job at the right time
- Blood pressure drug lisinopril causes gut swelling in man, 54, in rare case
- Rare Disease Week is an opportunity to show that rare is not invisible